Related references
Note: Only part of the references are listed.Rifaximin in the treatment of recurrent Clostridium difficile infection
E. Mattila et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps
Vishesh Kothary et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
P. Meyrat et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Stacy B. Menees et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome
Eric Shah et al.
AMERICAN JOURNAL OF MEDICINE (2012)
In Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy
Robert J. Carman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Current State of Clostridium difficile Treatment Options
Anilrudh A. Venugopal et al.
CLINICAL INFECTIOUS DISEASES (2012)
Current Status of Clostridium difficile Infection Epidemiology
Fernanda C. Lessa et al.
CLINICAL INFECTIOUS DISEASES (2012)
Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
Cosimo Prantera et al.
GASTROENTEROLOGY (2012)
RATES OF COMMONLY OCCURING INFECTIONS IN CIRRHOSIS PATIENTS REMAIN STABLE DURING LONG-TERM RIFAXIMIN TREATMENT
A. Sanyal et al.
JOURNAL OF HEPATOLOGY (2012)
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection
Kevin W. Garey et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Antibiotic Therapy for the Irritable Bowel Syndrome.
Jan Tack
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation.
Mark Pimentel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study
David T. Rubin et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2011)
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance
Dhara Shah et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Rifaximin Treatment in Hepatic Encephalopathy
Nathan M. Bass et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial
P. Patrick Basu et al.
Therapeutic Advances in Gastroenterology (2010)
Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: Experience with Rifaximin
Sergio Peralta et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response
Anthony Lembo et al.
GASTROENTEROLOGY (2008)
Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: An observation on non-absorbable antibiotics
I. Esposito et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Functional bowel disorders
George F. Longstreth et al.
GASTROENTEROLOGY (2006)
Rifaximin: A novel nonabsorbed rifamycin for gastrointestinal disorders
JA Adachi et al.
CLINICAL INFECTIOUS DISEASES (2006)
Rifaximin, a poorly absorbed antibiotic: Pharmacology and clinical potential
C Scarpignato et al.
CHEMOTHERAPY (2005)
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci
HL DuPont et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Share Paper
